Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes
2014 ASH Annual MeetingAlan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Label, Phase II, Dose-Finding Study of Sotatercept (ACE-011) in Patients With Low or Intermediate-1–Risk Myelodysplastic Syndromes or Nonproliferative Chronic Myelomonocytic Leukemia and Anemia Requiring Transfusion,” presented by Rami S. Komrokji, MD.
Related Videos
Linda J. Burns, MD, on the BLAST Study
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 379,
Sagar Lonial, MD, on the Phase III ASPIRE Trial
Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 79, “Carfilzomib...
Hagop Kantarjian, MD, on CAR T Cells in Relapsed/Refractory ALL
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380,
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 232, “Long-Term Comp...
Keith McCrae, MD, on Splenectomy in Immune Thrombocytopenia
Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial
Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “
